SeptiCyte™ LAB Differentiates Sepsis from Infection-Negative Systemic Inflammation in Critically Ill Children
SEATTLE, Sept. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability of SeptiCyte™ LAB to distinguish sepsis from infection-negative systemic inflammation in the pediatric intensive care population. The manuscript, which is available online and will be in the April 2017 issue of the publication, describes the first study to determine the feasibility of applying SeptiCyte™ LAB in pediatric populations.
"Sepsis is one of the most common causes of childhood death worldwide," said Professor Jerry Zimmerman, a pediatric intensivist at Seattle Children's Hospital and professor of pediatrics and anesthesiology at the University of Washington School of Medicine and the study's lead author. "A test that could rapidly discriminate between infection-negative systemic inflammation and sepsis, especially in its early stages when therapeutic intervention could be most effective, would have significant clinical utility for critically ill children suspected of sepsis."
In this prospective observational pilot study, SeptiCyte™ LAB was used to evaluate blood samples from children with clinical severe sepsis syndrome (CSSS), as compared to an infection-negative systemic inflammation subpopulation, children immediately post-cardiopulmonary bypass surgery (PCPB). SeptiCyte™ LAB was shown to have high accuracy (AUC, 0.99; 95% CI, 0.96-1.00) for discriminating critically ill children with CSSS versus children recovering from PCPB. In addition, the study indicates the assay results are not influenced by severity of the host response in terms of organ dysfunction.
"SeptiCyte™ LAB provides an accurate probability of sepsis in nearly 100% of the cases examined in a matter of hours, considerably shorter than the time required for conventional blood culture," said Dr. Roslyn Brandon, President and CEO of Immunexpress. "The results of this study provide the first evidence that our technology can be applied in the pediatric setting to rapidly provide physicians with critical diagnostic information in populations characterized with non-infectious and infectious systemic inflammation. We look forward to conducting a larger and broader investigation to examine the generalizability of SeptiCyte™ LAB in early identification of the septic child."
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with sepsis, at risk of sepsis, and suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system. Detecting the patient's septic immune response has the potential to identify sepsis earlier, faster and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen; the immune response is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes assays for readily available lab-based platforms, as well as point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.
Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.
Media Contacts: David Schull or Todd Davenport, Ph.D.Russo Partners(212) 845-4271(212) 845-4262 email@example.com firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/septicyte-lab-differentiates-sepsis-from-infection-negative-systemic-inflammation-in-critically-ill-children-300332758.html
SOURCE Immunexpress, Inc.